Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic
At the time the COVID-19 pandemic was declared there was no vaccine and other medical products were insufficient to meet demands. At the time intellectual property was considered a limitation to an effective pandemic response and the World Trade Organization considered a waiver of intellectual property addressed by the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The lesson from the COVID-19 pandemic and TRIPS waiver is that given enough time sufficient medical products will be delivered, albeit there remain some complicated delivery challenges and vaccine hesitancy issues. This column addresses the moment before that medical product saturation and the inherent limitation imposed by industry policies. The column concludes that the private sectors' motivating factors need to be integrated into the design of global public health pandemic responses from the start.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Journal of law and medicine - 30(2023), 3 vom: 09. Dez., Seite 538-554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lawson, Charles [VerfasserIn] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM368220796 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368220796 | ||
| 003 | DE-627 | ||
| 005 | 20240214233256.0 | ||
| 007 | tu | ||
| 008 | 240209s2023 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368220796 | ||
| 035 | |a (NLM)38332594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lawson, Charles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is Intellectual Property the COVID-19 Bad Guy? Lessons We Could Learn from the Pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a At the time the COVID-19 pandemic was declared there was no vaccine and other medical products were insufficient to meet demands. At the time intellectual property was considered a limitation to an effective pandemic response and the World Trade Organization considered a waiver of intellectual property addressed by the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The lesson from the COVID-19 pandemic and TRIPS waiver is that given enough time sufficient medical products will be delivered, albeit there remain some complicated delivery challenges and vaccine hesitancy issues. This column addresses the moment before that medical product saturation and the inherent limitation imposed by industry policies. The column concludes that the private sectors' motivating factors need to be integrated into the design of global public health pandemic responses from the start | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a TRIPS waiver | |
| 650 | 4 | |a industry policy | |
| 650 | 4 | |a intellectual property | |
| 650 | 4 | |a pandemics | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of law and medicine |d 1994 |g 30(2023), 3 vom: 09. Dez., Seite 538-554 |w (DE-627)NLM093752369 |x 1320-159X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:3 |g day:09 |g month:12 |g pages:538-554 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 3 |b 09 |c 12 |h 538-554 | ||